|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,824.50 GBX | +0.19% |
|
+1.08% | +35.50% |
| 12-12 | US FDA approves Innoviva's oral antibiotic for gonorrhea | RE |
| 12-12 | Surprise UK GDP Contraction Keeps FTSE 100 in the Red | MT |
| Capitalization | 73.26B 97.84B 83.35B 77.86B 135B 8,862B 147B 909B 353B 4,177B 367B 359B 15,240B | P/E ratio 2025 * |
13x | P/E ratio 2026 * | 11.4x |
|---|---|---|---|---|---|
| Enterprise value | 87.45B 117B 99.5B 92.94B 161B 10,579B 176B 1,085B 421B 4,987B 438B 429B 18,193B | EV / Sales 2025 * |
2.69x | EV / Sales 2026 * | 2.48x |
| Free-Float |
94.52% | Yield 2025 * |
3.57% | Yield 2026 * | 3.83% |
Last Transcript: GSK plc
| 1 day | +0.19% | ||
| 1 week | +1.08% | ||
| Current month | +1.87% | ||
| 1 month | +0.77% | ||
| 3 months | +21.35% | ||
| 6 months | +20.71% | ||
| Current year | +35.50% |
| 1 week | 1,769.5 |  | 1,838 |
| 1 month | 1,753 | | 1,853.5 |
| Current year | 1,242.5 | | 1,853.5 |
| 1 year | 1,242.5 | | 1,853.5 |
| 3 years | 1,242.5 | | 1,853.5 |
| 5 years | 1,242.5 | | 3,408.16 |
| 10 years | 1,242.5 | | 3,408.16 |
| Manager | Title | Age | Since |
|---|---|---|---|
Emma Walmsley
CEO | Chief Executive Officer | 56 | 31/03/2017 |
Julie Brown
DFI | Director of Finance/CFO | 63 | 30/04/2023 |
James Ford
CMP | Compliance Officer | - | 31/07/2018 |
| Director | Title | Age | Since |
|---|---|---|---|
Emma Walmsley
BRD | Director/Board Member | 56 | 31/12/2016 |
Hal Barron
BRD | Director/Board Member | 63 | 31/12/2017 |
Jonathan Symonds
CHM | Chairman | 67 | 31/08/2019 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 3.15% | 26 M€ | +12.27% | - |
| 2.97% | 62 M€ | +14.58% | - |
| 2.51% | 8 M€ | +23.59% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.19% | +1.08% | +37.23% | +25.62% | 97.84B | |
| +1.80% | +1.70% | +30.21% | +186.49% | 920B | |
| +0.75% | +4.78% | +44.31% | +18.06% | 510B | |
| -0.29% | -1.22% | +28.81% | +35.52% | 395B | |
| -0.35% | +1.90% | +25.12% | +3.11% | 340B | |
| -1.12% | -1.09% | +28.43% | +18.70% | 278B | |
| -0.45% | -1.48% | +20.24% | +24.41% | 254B | |
| +1.30% | +0.58% | -1.67% | -9.57% | 249B | |
| +0.45% | +3.73% | -57.41% | -30.85% | 224B | |
| +0.11% | -3.68% | +17.41% | +16.70% | 171B | |
| Average | +0.24% | +0.63% | +17.27% | +28.82% | 343.98B | |
| Weighted average by Cap. | +0.54% | +1.15% | +22.30% | +59.11% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 32.52B 43.43B 37B 34.56B 59.86B 3,934B 65.4B 403B 156B 1,854B 163B 160B 6,765B | 34.25B 45.75B 38.97B 36.4B 63.06B 4,144B 68.89B 425B 165B 1,953B 172B 168B 7,126B |
| Net income | 5.68B 7.59B 6.46B 6.04B 10.46B 687B 11.42B 70.46B 27.33B 324B 28.46B 27.86B 1,182B | 6.41B 8.56B 7.3B 6.82B 11.81B 776B 12.9B 79.55B 30.86B 366B 32.13B 31.46B 1,334B |
| Net Debt | 14.19B 18.96B 16.15B 15.09B 26.13B 1,717B 28.55B 176B 68.3B 809B 71.13B 69.63B 2,953B | 11.69B 15.61B 13.3B 12.42B 21.52B 1,414B 23.51B 145B 56.25B 667B 58.59B 57.35B 2,432B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 12/12/25 | 1,824.50 p | +0.19% | 11,917,520 |
| 11/12/25 | 1,821.00 p | +0.97% | 8,075,615 |
| 10/12/25 | 1,803.50 p | +1.15% | 6,940,562 |
| 09/12/25 | 1,783.00 p | -2.06% | 8,160,060 |
| 08/12/25 | 1,820.50 p | +0.86% | 5,964,836 |
Delayed Quote London S.E., December 12, 2025 at 04:35 pm
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- GSK Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition